AMG 424 is a novel, humanized, bispecific T cell-recruiting anti-CD3/CD38 antibody that targets multiple myeloma cancer cells through T-cell dependent redirected lysis.
In July 2020, Amgen announced a business decision not to proceed with the AMG 424 asset. Learn more...
SparkCures ID | 317 |
---|---|
Developed By | Amgen |
Generic Name | AMG 424 |
Treatment Classifications | |
Treatment Targets |
There are no resources, links or videos to display for this treatment.